CDIO חוב כולל להון Cardio Diagnostics Holdings, Inc.

The available price action for Cardio Diagnostics (CDIO) demonstrates a debt-to-equity ratio of 0.05 as the company implements AI genetic screening systems to combat cardiological pathologies. Market capitalization is based on the sale of tests to clinics practicing a preventive approach to heart health. Currently, financial stability relies on external investments, as the product go-to-market stage has not yet generated a stable cash flow.

A comparative analysis of the liability structure allows investors to assess the business's resilience to liquidity crises through the ratio of total liabilities to equity. This metric determines the degree of Cardio Diagnostics (CDIO) dependence on borrowed funds, which is critical for an AI innovator in cardiology scaling its DNA platforms. By analyzing the financial leverage via the total debt-to-equity ratio, one can judge the balance between aggressive technological growth and the debt load.